Successful treatment of refractory polymyositis with the immunosuppressant mizoribine: case report
Successful treatment of refractory polymyositis with the immunosuppressant mizoribine: case report
复制标题
免疫抑制剂咪唑立宾成功治疗难治性多发性肌炎：病例报告
DOI：
--
复制
发表时间：
2008
影响因子：
3.4
通讯作者：
Masataka Kuwana
中科院分区：
文献类型：
--
作者：
Akira Suwa;M. Hirakata;Y. Kaneko;Shinji Sato;Yasuo Suzuki;Masataka Kuwana
我们描述了一位在类风湿关节炎发病18年后出现抗jo -1抗体的多发性肌炎患者，并在病情加重时成功地使用免疫抑制药物米佐利滨治疗。在开始大剂量类固醇治疗后，她出现了糖尿病、脑梗死和心肌梗死。因此，首选免疫抑制剂作为二线药物。用150毫克/天的米佐利滨和8毫克/天的强的松龙治疗导致肌肉酶水平最终正常化。米佐利滨是一种嘌呤抗代谢物，可抑制T细胞活化/增殖和B细胞增殖。本病例提示米佐利滨治疗多发性肌炎的潜在疗效。
We describe a patient who presented with polymyositis with anti-Jo-1 antibodies at 18 years after the onset of rheumatoid arthritis and was successfully treated with the immunosuppressive drug mizoribine at the time of exacerbation. She had developed diabetes mellitus, cerebral infarction, and myocardial infarction after high-dose steroid therapy was initiated. Therefore, an immunosuppressant was preferred as the second-line agent. Treatment with 150 mg/day of mizoribine and 8 mg/day of prednisolone resulted in eventual normalization of muscle enzyme levels. Mizoribine is a purine antimetabolite that inhibits T cell activation/proliferation and B cell proliferation. The potential efficacy of mizoribine for polymyositis was suggested by this case.
影响因子：
5.9
作者：
JOFFE, MM;LOVE, LA;MILLER, FW
通讯作者：
MILLER, FW